BioFunding

ERC to boost EU basic research

23.01.2007

A new era in science funding has started this January with the inception of the European research Council (ERC). For the first time, the European Union will channel Euro 7.5 billion of its application-orientated research framework programme into basic research of outstanding excellence. For this year, Euro 292 million have already been earmarked for so-called ‘starting independent researcher grants’ from the Euro 54 billion budget of FP7 (2007-2013), making up one third of the annual Euro 1.25 billion budget of the ERC. In autumn, a second funding scheme termed ‘the advanced investigator grant’ will be introduced. In total, 40% of the ERC’s total budget will be channelled into biological research.

The first call, especially designed for postdoc researchers, was published at the end of December with the aim of supporting independent frontier research. “This is a signal to support not only research into applications but also to back excellent basic research”, said Prof. Ernst-Ludwig Winnacker, Secretary General of the ERC. “Up to now, little money has been allocated particularly to young researchers by the national research agencies. Furthermore, there is a lot of double work in European labs. With the ERC funds, we want to improve this”, stressed Winnacker.
The German science manager will act as an ‘interface’ between the 22 scientific experts of the ERC’s Scientific Council – which is responsible for ERC strategy, and will draft and overview the implementation of the annual working programme and the evaluation process – and an executive agency (dedicated implementation structure (DIS)/directorate S) of currently 85 staff, established by the European Commission. The agency will implement the working programme, the peer review, and the evaluation process.

Criteria for measuring scientific excellence

Currently, 19 thematic interdisciplinary panels of 10 experts each, which will be supported by up to 50 scientific referees each, will evaluate the project proposals in a 2-step procedure after pre-registration.
In the first step, a project outline (excellence, feasibility, methods) and the qualification of the principal investigator (funding ID, high impact publications, ability to initiate new lines of thinking, novelty of approaches), will be evaluated using a score, qualifying applicants with a score higher than 8 to enter phase 2. In the next step, the full proposal including an assessment of the research environment (e.g. infrastructure) and a presentation will be evaluated. The deadline for pre-proposals will be 25 April 2007. It is expected that the ERC will fund about 200 projects with Euro 100,000 to Euro 400,000 per year. The main challenge for the reviewers will be on identifying promising novel research ideas besides the research mainstream.
A similar funding mechanism has been already established by the US National Science Foundation, which supports US basic researchers (NIH-funded projects excluded) with funds of Euro 4.3 billion annually.
However, research excellence will not be the only criterion for research grants. Because the new funding mechanism is part of the European Union’s framework programme FP7 it will suffer from the same political limitations. There will, for example, not be any equal treatment of European researchers working on human embryonic stem cells, due to differences between national legislations.

Politics / Law

06.03.2012

The human race is at war with another species, and has been for thousands of years. Each of us in Europe swats dead dozens of the enemy every summer, and in the tropics they kill thousands of people with infectious diseases...

Tech Review

06.03.2012

The Philogen group is a specialist for therapies against cancer. Unlike other private companies, the Swiss-Italian firm has developed a rich pipeline of antibodies consisting of five different molecules being tested in 15...

Tech Review

06.03.2012

Success in the biopharmaceutical industry is mainly driven by the ability to innovate, and the continuous development of new products is crucial in that context. Shortening development times is key. The use of comprehensive...

Tech Review

06.03.2012

Zurich-based NeurImmune AG follows unconventional routes – for example, the company doesn’t rely on VC investors. And Neurimmune has also turned the drug discovery process upside down by taking its drug candidates from healthy...

Tech Review

06.03.2012

The use of bispecific antibodies recognising two different targets may allow improvement of clinical efficacy. A bispecific antibody for two growth factors that stimulate the formation of blood vessels – Ang2 (Angiopoietin-2) and...

Clinical Trial

02.03.2012

Sweden’s Karo Bio AB has been hit hard by toxicity issues with its lead compound eprotirome. The anti-cholesterol drug – which was in Phase III clinical development – proved unsafe in a long-term animal tests. The drug lead to...

Clinical Trial

01.03.2012

Inspiration Biopharmaceuticals Inc. reported on 22 February that its lead candidate drug proved successful in a clinical trial involving 12 patients who suffer from hemophilia B. The results were presented at the 5th Annual EAHAD...

Displaying results 21 to 30 out of 1982

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/2/article/erc-to-boost-eu-basic-research.html

Image Gallery

Stock list

All quotes

TOP

  • GW PHARMACEUTICALS (UK)305.50 GBP39.3%
  • NEWRON (CH)15.60 CHF20.0%
  • TOPOTARGET (DK)3.52 DKK16.9%

FLOP

  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.3%
  • WILEX (D)0.84 EUR-8.7%
  • GENFIT (F)22.42 EUR-8.1%

TOP

  • BIOTECH PHARMACON (N)18.80 NOK71.7%
  • WILEX (D)0.84 EUR47.4%
  • E-THERAPEUTICS (UK)27.75 GBP38.8%

FLOP

  • CYTOS (CH)0.17 CHF-93.8%
  • BIONOR PHARMA (N)2.11 NOK-47.3%
  • IMMUNICUM AB (S)16.60 SEK-36.2%

TOP

  • SILENCE THERAPEUTICS (UK)261.00 GBP6265.9%
  • IXICO (UK)68.00 GBP756.4%
  • PHARMING (NL)0.50 EUR733.3%

FLOP

  • CYTOS (CH)0.17 CHF-95.8%
  • EVOCUTIS (UK)0.22 GBP-91.8%
  • AGENNIX (D)0.04 EUR-77.8%

No liability assumed, Date: 23.04.2014

Current issue

All issues

Product of the week

Products

Events

All Events

Partner-Events

München

BioVaria 2014

Frankfurt am Main

7th DVFA Life Science Conference

White Paper